.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
McKesson
US Army
Baxter
Federal Trade Commission
Teva
Harvard Business School
Covington
Mallinckrodt
McKinsey

Generated: December 18, 2017

DrugPatentWatch Database Preview

TAKEDA Company Profile

« Back to Dashboard

What is the competitive landscape for TAKEDA, and what generic alternatives to TAKEDA drugs are available?

TAKEDA has twenty-one approved drugs.

There are eighty-three US patents protecting TAKEDA drugs and there have been two Paragraph IV challenges on TAKEDA drugs in the past three years.

There are one thousand and sixty-eight patent family members on TAKEDA drugs in fifty-nine countries and one hundred and twenty-eight supplementary protection certificates in fifteen countries.

Summary for TAKEDA

International Patents:1068
US Patents:83
Tradenames:22
Ingredients:16
NDAs:21
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms UsaDEXILANTdexlansoprazoleCAPSULE, DELAYED RELEASE;ORAL022287-002Jan 30, 2009ABRXYesYes► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaULORICfebuxostatTABLET;ORAL021856-002Feb 13, 2009RXYesYes► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaDEXILANTdexlansoprazoleCAPSULE, DELAYED RELEASE;ORAL022287-002Jan 30, 2009ABRXYesYes► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaACTOPLUS MET XRmetformin hydrochloride; pioglitazone hydrochlorideTABLET, EXTENDED RELEASE;ORAL022024-002May 12, 2009RXYesYes► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaNESINAalogliptin benzoateTABLET;ORAL022271-001Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaCOLCRYScolchicineTABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-006Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-006Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-002Jan 25, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaDEXILANTdexlansoprazoleCAPSULE, DELAYED RELEASE;ORAL022287-001Jan 30, 2009RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Takeda

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms UsaACTOSpioglitazone hydrochlorideTABLET;ORAL021073-001Jul 15, 1999► Subscribe► Subscribe
Takeda Pharms UsaDEXILANTdexlansoprazoleCAPSULE, DELAYED RELEASE;ORAL022287-002Jan 30, 2009► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-002Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaDEXILANTdexlansoprazoleCAPSULE, DELAYED RELEASE;ORAL022287-001Jan 30, 2009► Subscribe► Subscribe
Takeda Pharms UsaDUETACTglimepiride; pioglitazone hydrochlorideTABLET;ORAL021925-002Jul 28, 2006► Subscribe► Subscribe
Takeda Pharms UsaPREVPACamoxicillin; clarithromycin; lansoprazoleCAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL050757-001Dec 2, 1997► Subscribe► Subscribe
Takeda Pharms UsaDEXILANTdexlansoprazoleCAPSULE, DELAYED RELEASE;ORAL022287-001Jan 30, 2009► Subscribe► Subscribe
Takeda Pharms NaPREVACIDlansoprazoleFOR SUSPENSION, DELAYED RELEASE;ORAL021281-001May 3, 2001► Subscribe► Subscribe
Takeda Pharms UsaACTOSpioglitazone hydrochlorideTABLET;ORAL021073-003Jul 15, 1999► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-004Jan 25, 2013► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TAKEDA drugs

Drugname Dosage Strength Tradename Submissiondate
alogliptinTablets6.25 mg, 12.5 mg and 25 mgNESINA1/25/2017
alogliptin and metformin hydrochlorideTablets12.5 mg/500 mg and 12.5 mg/1000 mgKAZANO1/25/2017
febuxostatTablets40 mg and 80 mgULORIC2/13/2013
colchicineTablets0.6 mgCOLCRYS12/23/2011
pioglitazone hydrochloride and metformin hydrochlorideExtended-release Tablets15 mg/1000 mg and 30 mg/1000 mgACTOPLUS MET XR9/23/2011
dexlansoprazoleDelayed-release Capsule30 mgDEXILANT11/30/2010
dexlansoprazoleCapsule60 mgDEXILANT8/25/2010
pioglitazone hydrochloride and glimepirideTablets30 mg/2 mg and 30 mg/4 mgDUETACT12/22/2009
ramelteonTablets8 mgROZEREM7/22/2009
pioglitazone hydrochloride and metformin hydrochlorideTablets15 mg/500 mg and 15 mg/850 mgACTOPLUS MET3/6/2008
lansoprazoleDelayed-release Orally Disinte15 mg and 30 mgPREVACID12/27/2006
lansoprazoleDelayed-release Pellets/Capsul15 mg and 30 mgPREVACID12/5/2005

Non-Orange Book Patents for Takeda

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,339,064Benzimidazole compound crystal► Subscribe
7,795,428Dipeptidyl peptidase inhibitors► Subscribe
6,150,383 Pharmaceutical composition► Subscribe
8,318,669Method of regulating glucose metabolism, and reagents related thereto► Subscribe
6,156,773 Pharmaceutical composition► Subscribe
8,552,198Benzimidazole compound crystal► Subscribe
8,513,190Method of regulating glucose metabolism, and reagents related thereto► Subscribe
6,174,904 Pharmaceutical composition► Subscribe
6,323,225 Pharmaceutical composition► Subscribe
8,084,058Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Takeda Drugs

Country Document Number Estimated Expiration
Canada2602184► Subscribe
Argentina019935► Subscribe
Israel198844► Subscribe
European Patent Office2107905► Subscribe
Israel171782► Subscribe
Canada2737851► Subscribe
Denmark0885210► Subscribe
Hong Kong1118293► Subscribe
Argentina103423► Subscribe
China101553242► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Takeda Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014026Lithuania► SubscribePRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
2014013,C1436271Lithuania► SubscribePRODUCT NAME: VORTIOKSETINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA RUGSTIES PRISIJUNGIMO DRUSKA; REGISTRATION NO/DATE: EU/1/13/891 20131218
00569Netherlands► SubscribePRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN COMBINATIE MET METFORMINEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/12/780/001-028 20120720
8Finland► Subscribe
2010005Lithuania► SubscribePRODUCT NAME: FEBUXOSTATUM; REGISTRATION NO/DATE: EU/1/08/447/001-EU/1/08/447/004 20080421
0140037 00152Estonia► SubscribePRODUCT NAME: FEBUKSOSTAAT;REG NO/DATE: EU/1/08/447 23.04.2008
2010 00015Denmark► Subscribe
0140007 00126Estonia► SubscribePRODUCT NAME: ALOGLIPTIIN;REG NO/DATE: EU/1/13/844 23.09.2013
2014 00066Denmark► SubscribePRODUCT NAME: ALOGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER ALOGLIPTIN BENZOATE; REG. NO/DATE: EU/1/13/844/001-027 20130923
00705Netherlands► SubscribePRODUCT NAME: SITAGLIPTINE; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Fuji
Chubb
Baxter
Daiichi Sankyo
Merck
UBS
Boehringer Ingelheim
Accenture
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot